April 1 (Reuters) - Medical device maker Becton
Dickinson ( BDX ) has begun discussions to sell its life
sciences division, valued at $21 billion, and is in talks with
competitors such as Thermo Fisher Scientific ( TMO ) and Danaher ( DHR )
, the Financial Times reported on Tuesday.
(Reporting by Surbhi Misra in Bengaluru)